20cm速递丨BD交易火热，科技主线催化，关注科创200ETF国泰（589223）投资价值

Group 1 - The core viewpoint of the article highlights the rapid growth of BD transactions and the catalytic role of technology, emphasizing the investment value of the Guotai Sci-Tech 200 ETF (589223) [1] - Over the past decade, the Chinese pharmaceutical industry has undergone a transformation driven by policy support, leading to industrial upgrades [1] - The approval of the "Implementation Plan for Supporting the Development of Innovative Drugs" by the State Council in July 2024 marks a new phase in national strategic support for innovative drug development, optimizing various policies to promote breakthroughs [1] Group 2 - China has entered the first tier of global new drug research and development, with the number of self-developed First-in-Class (FIC) drugs increasing from 9 in 2015 to 120 in 2024, representing 31% of the global pipeline, second only to the United States [1] - The international recognition of the innovation and value of Chinese innovative drugs has led to a trend of globalization, with both independent international expansion and licensing-out models experiencing significant growth [1] - The Sci-Tech 200 Index, which aggregates small-cap stocks from the Sci-Tech Board, reflects the development direction of new productive forces, making the Guotai Sci-Tech 200 ETF (589223) an attractive option for investors looking to participate in hard-tech enterprises [2]